Observational studyEuropean journal of nuclear medicine and molecular imaging2018
Assessment of alteration in liver
Observational study in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Early prognostic stratification of follicular lymphoma through ¹⁸F-FDG PET/CT tumor metabolic parameters and clinical characteristics.EJNMMI research · 2026Article
- Impact of a deep progressive reconstruction algorithm on low-dose or fast-scan PET image quality and Deauville score in patients with lymphoma.EJNMMI physics · 2025Article
- Improved identification of tumors in 18F-FDG-PET examination by normalizing the standard uptake in the liver based on blood test data.International journal of computer assisted radiology and surgery · 2024Article
- The effect of hepatic steatosis on 18F-FDG uptake in PET-CT examinations of cancer Egyptian patients.European journal of hybrid imaging · 2023Article
- Development of a simple standardized scoring system for assessing large vessel vasculitis by 18F-FDG PET-CT and differentiation from atherosclerosis.European journal of nuclear medicine and molecular imaging · 2023Article
- The use of a visual 4-point scoring scale improves the yield ofEuropean journal of nuclear medicine and molecular imaging · 2021Article
- HYPHYCA: a prospective study in 613 patients conducting a comprehensive analysis for predictive factors of physiologicalEJNMMI research · 2020Article
- Comprehensive analysis of the influence of G-CSF on the biodistribution ofEJNMMI research · 2019Article
- Reply to the Letter to the Editor from Peters et al: On the use of the liver as a reference organ for Deauville scoring in lymphoma patients and how it may be affected by liver steatosis.European journal of nuclear medicine and molecular imaging · 2018Article
- Assessment of alteration in liverEuropean journal of nuclear medicine and molecular imaging · 2018Article
- The findings of 18World journal of nuclear medicineArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimOur aim was (1) to evaluate the prevalence of steatosis in lymphoma patients and its evolution during treatment; (2) to evaluate the impact of hepatic steatosis on
methodsOver a 1-year period, 358 PET scans from 227 patients [122 diffuse large B cell lymphoma (DLBCL), 57 Hodgkin lymphoma (HL) and 48 Follicular lymphoma (FL)] referred for baseline (n = 143), interim (n = 79) and end-of-treatment (EoT, n = 136) PET scans were reviewed. Steatosis was diagnosed on the unenhanced CT part of PET/CT examinations using a cut-off value of 42 Hounsfield units (HU). EARL-compliant SUL
resultsPrevalence of steatosis at baseline, interim and EoT PET was 15/143 (10.5%), 6/79 (7.6%) and 16/136 (11.8%), respectively (p = 0.62).Ten out of 27 steatotic patients (37.0%) displayed a steatotic liver on all examinations. Six patients (22.2%) had a disappearance of hepatic steatosis during their time-course of treatment. Only one patient developed steatosis during his course of treatment. Liver SUL
conclusionsSteatosis is actually a theoretical but not practical issue in most patients but should be recognised and corrected in appropriate cases, namely, for those patients scored DS4 with a percentage difference between the target lesion and the liver background lower than 30%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.